All patients received BIMZELX every four weeks (Q4W) to Week 16, then received either Q4W or Q8W depending upon response to treatment. Receiving Q4W to Week 16, then Q8W thereafter is the approved ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance. After five years of continued ...

The European Commission has cleared the drug as Bimzelx for the treatment of moderate to severe plaque psoriasis in adults, which is its first regulatory approval worldwide and comes six years ...

Brussels (Belgium), March 7, 2025 – 14:00 (CET) – UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ® (bimekizumab-bkzx) in moderate to ...

On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to ...

Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.1-4 "A ...

In psoriasis patients, 67.7% achieved complete skin clearance after five years of Bimzelx. In hidradenitis suppurativa, 63.6% had no or mild skin pain at two years, up from 10% at baseline.

Similar results were seen in all patients with PSO, including those with PsA at baseline Dual inhibition: BIMZELX ® is the first and only approved medicine designed to selectively inhibit both ...

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with ...

Similar results were seen in all patients with PSO, including those with PsA at baseline Dual inhibition: BIMZELX ® is the first and only approved medicine designed to selectively inhibit both ...